Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET
CRANFORD, N.J., Aug. 12,
2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced
that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming
developments.
Citius Chairman and CEO, Leonard
Mazur, will be joined by members of the management team. A
question and answer period will follow management's discussion.
Conference Call Details:
|
Date:
|
Tuesday, August 13,
2024
|
|
|
|
Time:
|
8:30 a.m. Eastern
Time
|
|
|
|
Dial
In:
|
1-888-243-4451 (U.S.
toll free)
1-412-542-4135
(international)
|
|
|
|
Webcast:
|
Register for the
webcast here. A replay will be available on the Citius website
(www.citiuspharma.com) for 90 days following the event.
|
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to the development and commercialization of
first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted
immunotherapy for an initial indication in the treatment of
cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also
includes Mino-Lok®, an antibiotic lock solution to salvage
catheters in patients with catheter-related bloodstream infections,
and CITI-002 (Halo-Lido), a topical formulation for the relief of
hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase
2b trial for Halo-Lido were completed
in 2023. Mino-Lok met primary and secondary endpoints of its Phase
3 Trial. Citius is actively engaged with the FDA to outline next
steps for both programs. For more information, please visit
www.citiuspharma.com.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-host-investor-call-to-discuss-recent-and-upcoming-developments-302219218.html
SOURCE Citius Pharmaceuticals, Inc.